Carcinoma of the colon and rectum with deregulation of insulin-like growth factor 2 signaling: clinical and molecular implications

Journal of Gastroenterology

Volumn 51, Issue 10, 2016, Pages 971-984

  Belharazem, Djeda ^a   Magdeburg, Julia ^a   Berton, Ann Kristin ^a   Beissbarth, Li ^b   Sauer, Christian ^a   Sticht, Carsten ^a   Marx, Alexander ^a   Hofheinz, Ralf ^a   Post, Stefan ^a   Kienle, Peter ^a   Ströbel, Philipp ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

AKT1; Colon cancer; IGF2; Imprinting; Wnt5a

Indexed keywords

BRCA2 PROTEIN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CYCLIN DEPENDENT KINASE 1; SOMATOMEDIN B; TRICIRIBINE; WNT5A PROTEIN; AKT1 PROTEIN, HUMAN; CDK1 PROTEIN, HUMAN; CEACAM6 PROTEIN, HUMAN; CELL ADHESION MOLECULE; CYCLIN DEPENDENT KINASE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IGF1R PROTEIN, HUMAN; IGF2 PROTEIN, HUMAN; IMP3 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PROTEIN KINASE B; PROTEIN P21; RNA BINDING PROTEIN; SOMATOMEDIN RECEPTOR; WNT5A PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DEREGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FEMALE; GENE; GENE ACTIVATION; GENE EXPRESSION; HUMAN; IGF2BP3 GENE; KPN2A GENE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECTUM CARCINOMA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR BIOPSY; WESTERN BLOTTING; CARCINOMA; COLORECTAL TUMOR; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENETIC EPIGENESIS; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; SURVIVAL RATE; TUMOR CELL LINE; VERY ELDERLY; WNT SIGNALING PATHWAY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BRCA2 PROTEIN; CARCINOMA; CELL ADHESION MOLECULES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASES; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOTYPE; GPI-LINKED PROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTORS, SOMATOMEDIN; RNA-BINDING PROTEINS; SURVIVAL RATE; WNT SIGNALING PATHWAY; WNT-5A PROTEIN;

EID: 84961217548     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-016-1181-5     Document Type: Article

References (45)

1. Pfeifer K. Mechanisms of genomic imprinting. Am J Hum Genet. 2000;67(4):777–87.
2. Kaneda A, Feinberg AP. Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res. 2005;65(24):11236–40.
3. Foulstone E, Prince S, Zaccheo O, et al. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol. 2005;205(2):145–53.
4. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501 Epub 2002/07/03.
5. Cui H, Onyango P, Brandenburg S, et al. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res. 2002;62(22):6442–6.
6. Rainier S, Johnson LA, Dobry CJ, et al. Relaxation of imprinted genes in human cancer. Nature. 1993;362(6422):747–9.
7. Ogawa O, Eccles MR, Szeto J, et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms’ tumour. Nature. 1993;362(6422):749–51.
8. Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Investig. 1994;94(1):445–8.
9. Cui H, Horon IL, Ohlsson R, et al. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med. 1998;4(11):1276–80.
10. Zhan S, Shapiro D, Zhan S, et al. Concordant loss of imprinting of the human insulin-like growth factor II gene promoters in cancer. J Biol Chem. 1995;270(47):27983–6.
11. Elkin M, Shevelev A, Schulze E, et al. The expression of the imprinted H19 and IGF-2 genes in human bladder carcinoma. FEBS Lett. 1995;374(1):57–61.
12. Randhawa GS, Cui H, Barletta JA, et al. Loss of imprinting in disease progression in chronic myelogenous leukemia. Blood. 1998;91(9):3144–7.
13. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science. 2003;299(5613):1753–5.
14. Nosho K, Kawasaki T, Ohnishi M, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia. 2008;10(6):534–41.
15. Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J clin oncol. 2002;20(4):1043–8.
16. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–50 Epub 2005/10/04.
17. Belharazem D, Kirchner M, Geissler F, et al. Relaxed imprinting of IGF2 in peripheral blood cells of patients with a history of prostate cancer. Endocrine connections. 2012;1(2):87–94 Epub 2013/06/20.
18. Lee SH, Bahn JH, Choi CK, et al. ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Mol Cancer Ther. 2008;7(12):3739–50 Epub 2008/12/17.
19. Moon Y, Bottone FG Jr, McEntee MF, et al. Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1. Mol Cancer Ther. 2005;4(10):1551–8 Epub 2005/10/18.
20. Nakagawa H, Chadwick RB, Peltomaki P, et al. Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci USA. 2001;98(2):591–6.
21. Cui X, Zhang P, Deng W, et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol. 2003;17(4):575–88.
22. Cruz-Correa M, Cui H, Giardiello FM, et al. Loss of imprinting of insulin growth factor II gene: a potential heritable biomarker for colon neoplasia predisposition. Gastroenterology. 2004;126(4):964–70.
23. Ito Y, Koessler T, Ibrahim AE, et al. Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. Hum Mol Genet. 2008;17(17):2633–43.
24. Cheng YW, Idrees K, Shattock R, et al. Loss of imprinting and marked gene elevation are 2 forms of aberrant IGF2 expression in colorectal cancer. International journal of cancer Journal international du cancer. 2010;127(3):568–77.
25. Ohta M, Sugimoto T, Seto M, et al. Genetic alterations in colorectal cancers with demethylation of insulin-like growth factor II. Hum Pathol. 2008;39(9):1301–8.
26. Sasaki J, Konishi F, Kawamura YJ, et al. Clinicopathological characteristics of colorectal cancers with loss of imprinting of insulin-like growth factor 2. Int J Cancer. 2006;119(1):80–3.
27. Maenaka S, Hikichi T, Imai MA, et al. Loss of imprinting in IGF2 in colorectal carcinoma assessed by microdissection. Oncol Rep. 2006;15(4):791–5.
28. Nishihara S, Hayashida T, Mitsuya K, et al. Multipoint imprinting analysis in sporadic colorectal cancers with and without microsatellite instability. Int J Oncol. 2000;17(2):317–22.
29. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38(7):787–93.
30. Ogino S, Cantor M, Kawasaki T, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut. 2006;55(7):1000–6.
31. Shiovitz S, Bertagnolli MM, Renfro LA, et al. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology. 2014;147(3):637–45.
32. Naito T, Nosho K, Ito M, et al. IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions. World J Gastroenterol. 2014;20(29):10050–61.
33. Baba Y, Nosho K, Shima K, et al. Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastroenterology. 2010;139(6):1855–64.
34. Cancer Genome Atlas. N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7.
35. Li X, Nadauld L, Ootani A, et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat Med. 2014;20(7):769–77.
36. Sakatani T, Kaneda A, Iacobuzio-Donahue CA, et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science. 2005;307(5717):1976–8.
37. Harper J, Burns JL, Foulstone EJ, et al. Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting. Cancer Res. 2006;66(4):1940–8.
38. Kaneda A, Wang CJ, Cheong R, et al. Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc Natl Acad Sci USA. 2007;104(52):20926–31.
39. Tada Y, Yamaguchi Y, Kinjo T, et al. The stem cell transcription factor ZFP57 induces IGF2 expression to promote anchorage-independent growth in cancer cells. Oncogene. 2015;34(6):752–60.
40. Hassan AB, Howell JA. Insulin-like growth factor II supply modifies growth of intestinal adenoma in Apc(Min/+) mice. Cancer Res. 2000;60(4):1070–6.
41. Morali OG, Delmas V, Moore R, et al. IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene. 2001;20(36):4942–50.
42. Gujral TS, Chan M, Peshkin L, et al. A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. Cell. 2014;159(4):844–56.
43. Endo M, Nishita M, Fujii M, et al. Insight into the role of wnt5a-induced signaling in normal and cancer cells. Int Rev Cell Mol Biol. 2015;314:117–48.
44. Klenova EM, Morse HC 3rd, Ohlsson R, et al. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol. 2002;12(5):399–414.
45. Pan Y, He B, Lirong Z, et al. Gene therapy for cancer through adenovirus vectormediated expression of the Ad5 early region gene 1A based on loss of IGF2 imprinting. Oncol Rep. 2013;30(4):1814–22.